为争夺Metsera，辉瑞已迅速跟进，将其收购报价提升至与竞争对手诺和诺德完全相同的水平——总价最高可达100亿美元。此举使这场激烈的竞购战进 入白热化阶段。两大巨头争夺的是Metsera在减肥药领域的潜力管线，包括一款月度注射剂，意图在预计规模将达千亿美元的减肥药市场中抢占先机。 周一美国市场一日内宣布四笔总额超800亿美元的大型交易，将今年的并购狂潮推向新高。在此背景下，制药巨头辉瑞与诺和诺德对"减肥药新 贵"Metsera的竞购战也进入白热化阶段。 据英国《金融时报》援引两位知情人士消息，辉瑞已在周三的截止日期前提交了新报价，将方案提升至与诺和诺德持平的水平：每股86.20美元，总价 最高100亿美元。 这场收购战的核心，是Metsera公司前景广阔的减肥药产品管线，其中包括一款可能改变市场规则的月度注射剂。 在当前由诺和诺德的Ozempic和礼来主导的市场中，任何能够提供更便捷、高效治疗方案的公司，都可能获得巨大的竞争优势。 对于诺和诺德而言，收购Metsera是巩固其市场领导地位的防御性举措。而对于辉瑞，这则是一次关键的进攻，旨在快速切入这个预计到本世纪末市场 规模将超过1000亿美元的黄金赛道。 ...

周一美国市场一日内宣布四笔总额超800亿美元的大型交易，将今年的并购狂潮推向新高。在此背景下，制药巨头辉瑞与诺和诺德对"减 肥药新贵"Metsera的竞购战也进入白热化阶段。 据英国《金融时报》援引两位知情人士消息，辉瑞已在周三的截止日期前提交了新报价，将方案提升至与诺和诺德持平的水平：每股 86.20美元，总价最高100亿美元。 此举使辉瑞得以继续留在牌桌上。此前，Metsera董事会曾判定其丹麦竞争对手诺和诺德的方案更优。辉瑞与诺和诺德正在激烈角逐，以 期将这家拥有潜力管线的生物科技公司收入囊中。 一波三折的竞购流程 这场竞购战充满了戏剧性的转折。最初，辉瑞在9月份已与Metsera达成初步协议。但上周，诺和诺德突然发起公开的非约束性要约，意 图"闯入"这笔交易，从而引发了一场激烈的竞购。 据报道，本周二，双方均提高了报价。诺和诺德的方案为每股62.20美元预付款及24美元的后续里程碑付款，总计每股86.20美元，被 Metsera董事会认定为"更优要约"。当时辉瑞的报价为每股70美元，对Metsera的估值约为81亿美元。 仅一天后，辉瑞便迅速将报价提升至与诺和诺德持平的水平。根据合并协议条款，若诺和诺 ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: "Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will con ...

For more on all this, let's bring in Beimo head of healthc care research, Evan David Seager. Evan, great to have you with us. >> Thank you for having me.>> Um, this is really becoming a battle over Meter. Is Metera worth this much. And who is it worth more to, Novo or Fizer.>> Well, I think Metser is definitely worth this much. As you know, the obesity market is likely to be in our estimates upwards of $130 billion when you lump in diabetes. So, there is a big opportunity here.And right now, it's only Lily ...

For more on all this, let's bring in Beimo head of healthc care research, Evan David Seager. Evan, great to have you with us. >> Thank you for having me.>> Um, this is really becoming a battle over Meter. Is Metera worth this much. And who is it worth more to, Novo or Fizer.>> Well, I think Metser is definitely worth this much. As you know, the obesity market is likely to be in our estimates upwards of $130 billion when you lump in diabetes. So, there is a big opportunity here.And right now, it's only Lily ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. "We remain confident in the merits of our claims and our belief that Metsera has acted in breach of its contractual obligations and that Metsera's directors have breached the. ...

Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter. ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk. ...

A judge denied Pfizer’s request to temporarily block Novo’s $10 billion bid to acquire the obesity startup Metsera, saying the US pharmaceutical company’s objections to the deal don’t warrant a delay https://t.co/MQfqucbmeh ...

A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $... ...